Dexcom INC Form 4 insider transactions

Karen M. Dahut, a director of DexCom Inc., reported acquiring 2,613 shares of common stock on May 22, 2024, through a restricted stock unit (RSU) award.

Director Richard Collins reports acquisition of 2,632 shares of DexCom stock via a restricted stock unit (RSU) award.

Nicholas Augustinos, a director at DexCom Inc., received 2,618 shares of common stock on May 22, 2024, as part of a restricted stock unit (RSU) award.

Director Steven Altman reported the acquisition of 2,613 shares of DexCom common stock through a restricted stock unit (RSU) award.

Eric Topol, a director at Dexcom Inc., transferred shares of common stock from direct ownership to Topol Family Holdings, LLC on May 18, 2024.

Director Barbara Kahn transferred shares of Dexcom Inc. common stock from direct ownership to a trust on May 18, 2024.

Mark G. Foletta, a director at Dexcom Inc., transferred 3,306 shares of common stock from direct ownership to a family trust on May 18, 2024.

Director Karen M Dahut transferred shares of Dexcom Inc. from direct ownership to a trust, according to a recent SEC Form 4 filing.

Director Richard Alexander Collins transferred shares of Dexcom Inc. common stock to the Richard A. Collins Revocable Trust on May 18, 2024.

Director Nicholas Augustinos transferred shares of Dexcom Inc. common stock to the Kirschner/Augustinos Revocable Trust.

Director Steven R. Altman transferred 2,885 shares of Dexcom Inc. common stock from direct ownership to the Altman Family Trust on May 18, 2024.

EVP Matthew Dolan sold 2,423 shares of DexCom stock at $126.58 per share on May 15, 2024, under a pre-arranged 10b5-1 trading plan.

DexCom's EVP and Chief Legal Officer, Michael Jon Brown, sold 629 shares of common stock at $126.25 per share under a pre-arranged 10b5-1 trading plan.

Matthew Dolan, EVP of Strategy and Corporate Development at Dexcom Inc., sold 1,990 shares of common stock at $137.81 per share on April 15, 2024, under a pre-arranged 10b5-1 trading plan.

Dexcom's CEO, Kevin Sayer, sold shares of common stock on April 8, 2024, under a pre-arranged 10b5-1 trading plan.

Michael Jon Brown, EVP and Chief Legal Officer of Dexcom Inc., sold shares of Dexcom stock on March 28, 2024, under a pre-arranged 10b5-1 trading plan.

EVP and Chief Human Resources Officer of Dexcom Inc., Sadie Stern, sold 4,137 shares of common stock on March 25, 2024, under a pre-arranged 10b5-1 trading plan.

Matthew Dolan, EVP of Strategy & Corporate Development at Dexcom Inc., sold shares of common stock on March 15, 2024, under a pre-arranged 10b5-1 trading plan.

Dexcom's CFO, Jereme Sylvain, sold 11,661 shares of common stock on March 12, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Sadie Stern, EVP Chief Human Resources at Dexcom Inc., sold shares to cover tax obligations related to vesting RSUs and under a pre-arranged 10b5-1 trading plan.

Dexcom's CEO, Kevin Sayer, executed multiple sales of common stock on March 12, 2024, primarily to cover tax obligations related to vesting RSUs and under a pre-arranged 10b5-1 trading plan.

EVP and COO Jacob Steven Leach reports the sale of shares to cover tax obligations and a gift of shares to a charitable fund.

Teri L Lawver, EVP and Chief Commercial Officer of Dexcom Inc., sold shares to cover tax withholding obligations related to vesting restricted stock units.

Matthew Dolan, EVP of Strategy and Corporate at Dexcom Inc., sold 6,710 shares of common stock on March 12, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Michael Jon Brown, EVP and Chief Legal Officer of Dexcom Inc., sold 8,799 shares of common stock on March 12, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Executive Vice President and CFO of DexCom, Jereme M. Sylvain, reports the acquisition of 26,053 shares of common stock through a restricted stock unit grant.

Sadie Stern, EVP and Chief Human Resources Officer of DexCom Inc., reports the acquisition of 21,711 restricted stock units.

Dexcom's CEO, Kevin Sayer, reports acquiring 51,692 shares of common stock through a grant of restricted stock units.

Executive Vice President and Chief Operating Officer of DexCom, Jacob Steven Leach, reports the acquisition of 26,053 shares of common stock through a grant of restricted stock units.

Teri L Lawver, EVP and Chief Commercial Officer of DexCom Inc., reports acquiring 26,053 shares of common stock through a grant of restricted stock units.